 | |
| Names | |
|---|---|
| Preferred IUPAC name (4S,5R)-5-[3,5-Bis(trifluoromethyl)phenyl]-3-{[4′-fluoro-2′-methoxy-5′-(propan-2-yl)-4-(trifluoromethyl)[1,1′-biphenyl]-2-yl]methyl}-4-methyl-1,3-oxazolidin-2-one | |
| Other names MK-0859 | |
| Identifiers | |
3D model (JSmol) | |
| ChEMBL | |
| ChemSpider |
|
| KEGG |
|
| UNII | |
| |
| |
| Properties | |
| C30H25F10NO3 | |
| Molar mass | 637.51 g·mol−1 |
Except where otherwise noted, data are given for materials in theirstandard state (at 25 °C [77 °F], 100 kPa). | |
Anacetrapib is aCETP inhibitor which was being developed to treatelevated cholesterol levels in an effort to preventcardiovascular disease.[1] In 2017 its development was abandoned byMerck.[2]
In 2017 REVEAL trial anacetrapib was shown to decrease the risk of repeat heart attacks in high-risk patients with previous acute coronary events.[3]
Other CETP inhibitors:[citation needed]
